This study focused on the association of extrinsic alkaline phosphatase (AP) activity with both early and advanced calcification of glutaraldehyde-pretreated bovine pericardial bioprosthetic (GPBP) tissue, and the inhibition of both calcification and AP activity by pre-incubation in diphosphonates (sodium-ethanehydroxydiphosphonate [NaEHDP], aminopropanehydroxydiphosphonate IAPD]) and metallic salts (FeCI,, Ga(NO&, AIQ). GPBP specimens were implanted subcutaneously in 3 wk old male rats after ore-incubation. Following explantation of the tissue at 72 h and 21 d, calcification was assessed tnorphologically by light microscopy and chemically by atomic adsorption spectroscopy for calcium content and by molybdate complexation for phosphorus. AP activity was characterized by enzymatic hydrolysis of paranitrophenyl phosphate and by histochemical studies. In both control and pretreated groups, AP levels were greater in 72 h explants than 21 d retrievals, which demonstrated extensive calcification in control explants. All pre-incubations that resulted in inhibition of calcification after 21 d, except for APD, were associated with 72 h AP content which was lower than control specimens. The typical time of initiation of calcification was 72 h, as determined by previous studies with this model system. Covalently bound APD inhibited calcification. Increased AP activity in the APD group may be due to the toxicity of this agent with resultant acute inflammation, or other incompletely understood effects of diphosphonates on calcification and AP. Furthermore, EHDP and Ga3' incubations were also associated with decreased GPBP AP at 72 h compared to control, but were not effective for inhibiting calcification after 21 d. We concluded that inhibition of peak GPBP AP activity is not necessarily associated with the prevention of GPBP mineralization.
Effects of metallic ions and diphosphonates on inhibition of pericardial bioprosthetic tissue calcification and associated alkaline phosphatase activity Danielle Hirsch, Frederick J. Schoen* and Robert J. Levy School, Ann Arbor, and *Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA This study focused on the association of extrinsic alkaline phosphatase (AP) activity with both early and advanced calcification of glutaraldehyde-pretreated bovine pericardial bioprosthetic (GPBP) tissue, and the inhibition of both calcification and AP activity by pre-incubation in diphosphonates (sodium-ethanehydroxydiphosphonate [NaEHDP], aminopropanehydroxydiphosphonate IAPD]) and metallic salts (FeCI,, Ga(NO&, AIQ) . GPBP specimens were implanted subcutaneously in 3 wk old male rats after ore-incubation. Following explantation of the tissue at 72 h and 21 d, calcification was assessed tnorphologically by light microscopy and chemically by atomic adsorption spectroscopy for calcium content and by molybdate complexation for phosphorus. AP activity was characterized by enzymatic hydrolysis of paranitrophenyl phosphate and by histochemical studies. In both control and pretreated groups, AP levels were greater in 72 h explants than 21 d retrievals, which demonstrated extensive calcification in control explants. All pre-incubations that resulted in inhibition of calcification after 21 d, except for APD, were associated with 72 h AP content which was lower than control specimens. The typical time of initiation of calcification was 72 h, as determined by previous studies with this model system. Covalently bound APD inhibited calcification. Increased AP activity in the APD group may be due to the toxicity of this agent with resultant acute inflammation, or other incompletely understood effects of diphosphonates on calcification and AP. Furthermore, EHDP and Ga3' incubations were also associated with decreased GPBP AP at 72 h compared to control, but were not effective for inhibiting calcification after 21 d. We concluded that inhibition of peak GPBP AP activity is not necessarily associated with the prevention of GPBP mineralization. The present study was carried out to understand the effects of diphosphonates and metallic salts on both calcification and AP activity during dystrophic mineralization of rat subdermal implants of GPBP. The goals of this study were to: (1) document the effects of various inhibitors of GPBP calcification on early (72 h) and late (21 d) mineralization and AP accumulation in rat subdermal implants; (2) to examine further the morphologic distribution of AP with either progression or inhibition of GPBP mineralization: and (3) to assess the effects of possible calcification inhibitors on the Ca-P mineral phase, as indicated by Ca/P ratios,
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MATERIALS AND METHODS
Materials
Electron microscopy-grade glutaraldehyde was purchased as an 8% aqueous solution (Polyscience, Warrington, PA, USA). The buffer used for cross-linking and incubation of the drugs included 50 mM N-2-hydroxyethylpiperazine-~'-2-ethanesulphonic acid (HEPES, Sigma Chemical, St Louis, MO, USA) with 0.1 M NaCl (EM Science, Cherry Hill, NJ, USA OH, USA). L-ascorbic acid was purchased from Fisher Chemical (FairLawn, NJ, USA), 2-amino-2-methyl-l-propanol, set-butanol, p-nitrophenyl phosphate (pnpp) and p-nitrophenol (pnp) were also obtained from Sigma.
Methods
In vitro incubations Fresh mature bovine parietal perica~ium was obtained from the slaughter house (P. Dunbar, Milan, MI, USA) and immediately cross-linked for 24 h in 0.6% glutaraldehyde at pH 7.4 (50 mM HEPES buffer) at 4"C, then stored for 2-4 wk in 0.2% glutaraldehyde in the same buffer at 4"C, as described previously5,6123. GPBP was cut into 1 cm diameter pieces and rinsed free of glutaraldehyde.
Following fixation and storage, the GPBP pieces were pre-incubated for 24 h at room temperature in either APD, or NaEHDP both at concentrations of 0.1 M, buffered to pH 7.4 plus NaCl(O.1 M). GPBP pieces were also pre-incubated in several metallic salt solutions at pH 3 (0.001 M HCl, NaCl 0.1 M) including AlCl, (0.1 M), Ga(NO,), (0.1 M), FeCl, (both 0.1 M and lo-* M). Control specimens of GPBP were pre-incubated in either pH 7.4 (50 mM HEPES) or pH 3(0.001 M HCl) solutions (0.1 M NaCl) for 24 h at room temperature.
Im~iant and ~trjeva~ methods
After pie-incubation in the various solutions, the GPBP specimens were washed with sterile saline, and then implanted subdermally in male, weanling rats (50-60 g, CD, Sprague-Dawley, Charles River Laboratories, Burlington, MA, USA) according to methods described previously ', '3 15* "9 23, The rats were anaesthetized by an i.m. injection of ketamine hydrochloride and xylazine.
Ten GPBP specimens were implanted subdermally per rat (six in the abdominal wall and four in the dorsal wall) (five rats per group study). At 72 h, five pieces (from the abdominal implant site) were removed under anaesthesia. After 21 d, the rats were killed by CO, asphyxiation and the remaining samples retrieved.
Biochemical analysis
Explants were rinsed with copious volumes of saline and deionized water, freeze-dried, minced and subjected to acid hydrolysis as described previously5, 23, Aliquots of the hydrolysates were analysed for calcium by atomic absorption and for phosphorus using a molybdate complexationz4.
AP enzymatic activity was quantitated as described previously . l2 Briefly, butanol extracts of 5-6 mg GPBP samples were assayed for hydrolysis of pnpp normalized by Lowry protein contentz5 (pH 10.4 and 37% at a wave length of 405 nm using a Lambda 3B spectrophotometer (Perkin-Elmer, Oak Brook, IL, USA).
A representative sample of each GPBP explant was placed in Karnovsky's fixative'" for subsequent morphoBiomaterials 1993, Vol. 14 NO. 5 * pg/mg of dried tissue. The sections were incubated at 37°C for 30 min in a medium for AP modified from Gomoriz7 containing 50 ml of 5 mM MgCl, in distilled water, 1 ml Naphtol AS-MX phosphate in pH 10.5 buffer (Sigma), and 25 mg Fast Red TR or Fast Blue RR (Sigma) as described previously".
RESULTS
The calcium and phosphorus levels, together with the AP activity data at 72 h and 21 d, are summarized in Table 1 (Figure 2) . Morphological assessment qualitatively confirmed these results (Figures 2 and 3) . Although covalently bound APD significantly inhibited calcification in 21 d explants compared to controls (which were heavily calcified), maximal AP levels for all groups at 21 d were noted in the APD group (Figures 2 and 3 Ga3+ explants demonstrated the highest P levels of all groups after 21 d. These may nucleate further Ca-P deposition.
Ca/P molar ratios of the 21 d explant groups demonstrated were consistent with the presence of calcium phosphate for the control groups and the FeCl, (low4 M) specimens. However, the calcified GafNO,), and NaEHDP groups each demonstrated a relatively higher phosphorus content and hence lower CaiP ratios than usually noted with hydroxyapatite deposition.
DISCUSSION
Interestingly, peak GPBP AP activities were noted on the 72 h explants regardless of pre-incubation in solutions of diphosphonates or metallic ions. Earlier results showed that AP activity peaks in the first 72 h in control GPBP rat subdermal explants: by this time calcification is also initiated".
However, comparisons between the various groups (control and pre-incubation) did not reveal a trend consistently linking reduced GPBP with inhibition of calcification.
Thus, although AP activity and inhibition of AP may be associated with the onset and progression of GPBP calcification, the present results support the view that AP may be one of several determinants of the pathogenesis of GPBP calcification. Therefore, AP inhibition or enhancement by various inhibitors may not reveal the importance of AP in this setting. Furthermore, previous work from our group has shown that extrinsic GPBP AP activity declines following its peak at 72 h as mineralization progresses. Comparable observations were reported in studies of the onset of bone mineralization involving endochondral MV calcification". In the case of MVs, this decline in AP activity is not due to proteolysis, but rather to the calcification process itself". The direct inhibitory effect of hydroxyapatite on AP, along with the loss of metal ions from the AP active site, are thought to contribute to the decline in AP activity during MV calcification.
This mechanism may also be operative in GPBP calcification.
The mechanism by which AP activity is promoted in GPBP mineralization
is not yet understood. AP-active sites are activated by metal ions's, such as Zn2+ and Mg'+. The A13+, Fe3+ and Ga3+ ions probably can compete with Zn2+ and Mgz+ at the enzyme's metallo-binding sites, and thereby inhibit the phosphohydrolase activity. The A13+, Fe3+ and Ga3+ ions (10-l M) in the GPBP tissues were able to inhibit AP activity, although less so with Ga3+ than the others. However, despite this level of enzyme inhibition by the Ga(NO,), pre-incubation, this pretreatment was not effective in inhibiting calcification. These results further suggest that, although AP activity may be associated with the onset and progression of GPBP mineralization, it may not be causal or essential for the pathogenesis.
Furthermore, earlier work has shown that either A13+ or Fe3+ salts act by binding to devitalized GPBP cells, and to membrane loci that are rich in phosphorus, thereby preventing the crystallization of hydroxyapatite at these sites". It may be argued that Fe3+ or A13+ lowered AP levels in our studies by a critical increment, thereby reducing GPBP calcification.
However, A13+, Fe3+ and other metal ions can inhibit mineralization by other mechanisms.
A13+ ions can absorb on to hydroxyapatite crystals and severely inhibit both hydroxyapatite formation and dissolution in vitrozgl 30. Many metals can interfere with hydroxyapatite crystal growth in vitro by either competing with Ca '+ for sites in the crystal lattice or by adsorbing to the crystal surface3'. A13+ and Zn2+ are found to inhibit MV mineralization3'.
Similarly, in the GPBP subdermal rat implants, the lowest molecular weight metal ions (Al < Fe < Ga, according to atomic weight] showed the strongest inhibitory effects on GPBP calcium accumulation.
In fact, the greater the molecular weight of the metal atom of interest, the lower degree of calcification inhibition noted. A13+, the smallest ion in relation to Fe3+ and Ga3+ was the most effective in calcification inhibition: Ga3+cation which is the largest metal ion (used in this study] was unable to prevent GPBP calcification. Furthermore, the higher phosphorus content of the Ga3+ 21 d explants suggests that high levels of nonapatitic phospho-mineral (perhaps Ga-phosphates) may be predisposed to form after Ga3+ pretreatment. Therefore, these metallic ion pretreatments may be associated with unusual phospho-mineral complexes involving, perhaps, phospholipids or metallo-phosphates other than hydroxyapatite. However, the present experimental design does not permit a conclusive resolution of these issues. APD pre-incubation inhibited GPBP calcification, but was associated with AP activity higher than controls. APD in clinical use has been associated with adverse effects related to cytotoxicity, as well as inflammatory gastrointestinal and dermatologic side effects33'34. The morphological results in the present study demonstrated an exuberant inflammatory response to the APD implants, and thus the higher level of AP may reflect enzyme activity from inflammatory cells or cells damaged due to toxic processes, rather than calcification-related events.
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It would have been helpful in this regard to have quantitated the extent of inflammatory cell infiltration, However, this was beyond the scope of the present studies. Furthermore, earlier results from our group have shown that APD pre-incubation of GPBP was associated with unstable covalent binding of APD to GPBP. Thus APD is continuously leaching out of the tissue, and may thereby cause regional toxicity near the GPBP implant, which could lead to increased AP activity related to inflammation, but probably spatially dissociated and unrelated to calcification.
Conversely, NaEHDP pre-incubation, which did not inhibit calcification, resulted in a slightly lower AP activity in the 72 h explants compared to the controls. However, the net decline in AP activity for the NaEHDP explant groups was comparable to that of calcified controls ( Figure I) . Furthermore, previous work from our group has demonstrated that NaEHDP rapidly diffuses out of GPBP tissue following pre-incubation, unlike Fe3+, A13+ and APD, which remain more closely associated with GPBP tissue35. Thus, no persistent anticalcification effects occurred in the NaEHDP group, and the decline in AP activity was comparable to controls, as might be expected.
In addition, elevated phosphorus levels were noted in the calcified 21 d NaEHDP explants, in which a Ca/P molar ratio was noted comparable to that of the Ga explants.
CONCLUSIONS
The peak levels of AP in rat subdermal GPBP implants were noted at 72 h in both controls and specimens pretreated with either calcification inhibitors, or related compounds which did not inhibit calcification. Thus, peak GPBP AP activity was present at 72 h, regardless of pretreatment conditions. All inhibitors of calcification [except APD) were associated with lower 72 h AP levels than controls, including pretreatments ineffective for calcification inhibition, such as Ga"+ and EHDP. Thus reduced AP at 72 h is not related to inhibition of calcification. Therefore, the results of the present experiments support the view that peak AP (72 h) is not necessarily associated with the ultimate progression GPBP calcification. 
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